Meet our Executive Team
Raphael Nir, PhD
President & Chief Scientific Officer
Dr. Raphael Nir has served as President and Chief Scientific Officer of SBH Sciences since co-founding the company in 1997. He started SBH Sciences to fulfill his dream of becoming a key player in the biotech arena, and to help companies develop drugs. Under his management, SBH Sciences has become a leading supplier of recombinant cytokines and a preferred discovery research service provider.
Raphael is an ambitious entrepreneur and has co-founded seven additional biotech and diagnostics companies: Karyopharm Therapeutics, SBH Diagnostics, Woodland Biosciences, Galectin Sciences, Alma Bio Therapeutics, Vuja De Sciences and NeuroDex. To fulfill his vision and help startup companies, he co-founded two additional companies; Sky Ventures and ABI-LAB; a 9-year old bio-incubator located in Natick, MA, currently housing 45 biotechnology companies.
One day however a small line of blind text by the name of Lorem Ipsum decided to leave for the far World of Grammar. The Big Oxmox advised her not to do so, because
Tami Rashal, M.D. MBA
Chief Medical Officer
Tami is the Chief Medical Officer of SBH Sciences and SBH Bioventure, bringing over a decade of experience in clinical research, drug development, and hospital practice. A distinguished board-certified hematologist-oncologist and accomplished entrepreneur, Dr. Rashal has successfully led three New Drug Applications (NDAs) and multiple Investigational New Drug (IND) submissions, demonstrating her expertise in advancing novel therapies to patients.
At SBH Sciences, Dr. Rashal plays a pivotal leadership role in expanding the company’s service offerings. Her focuses includes comprehensive IND submission support, medical and regulatory strategy development, protocol design and clinical trial execution, and enhanced medical affairs including engagement with Key Opinion Leaders (KOLs) and development of PDX models. In addition to expanding SBH’s service offerings, Dr. Rashal will focus on supporting biotech startups, leading due diligence, and fostering opportunities for non-dilutive funding to ensure long-term success and sustainability. Her strategic insights and collaborative approach will play a key role in SBH Sciences’ continued growth and success.
Before joining SBH Sciences. Dr. Rashal was the CEO of Merlin Health, an AI-based clinical trial decision-making tool, where she demonstrated her ability to drive complex projects and lead high-performing cross-functional teams to success.
Dr. Rashal completed her internal medicine training at Sheba Medical Center (Tel Hashomer) and her hematology-oncology fellowship at Sourasky Medical Center (Ichilov). She earned her M.D. from Semmelweis University and an MBA in Health Care Administration from Tel Aviv University.
One day however a small line of blind text by the name of Lorem Ipsum decided to leave for the far World of Grammar. The Big Oxmox advised her not to do so, because
Adam Nir
Chief Diagnostic Officer
Adam Nir serves as the Chief Diagnostic Officer at SBH Sciences, bringing over a decade of expertise in biomarker analysis and diagnostic testing.
He leads the biomarker department with precision, overseeing the seamless execution of complex, high-impact projects that drive scientific advancements. His extensive knowledge in ELISA development, multiplex analysis, and automated Western technology enables SBH Sciences to deliver cutting-edge, reproducible results that support breakthrough discoveries.
In 2024, Adam and his team provided expert biomarker analysis and diagnostic support to over 40 biotech companies, ensuring the highest standards of accuracy and reliability. Under his leadership, the laboratory adheres to Good Laboratory Practice (GLP) guidelines, maintaining the integrity and reproducibility of all data. Adam plays a pivotal role in strategic client support, offering comprehensive data analysis, optimizing project workflows, and providing scientific guidance that drives innovation.
Adam holds a Master of Arts in International Relations and a Master of Strategic Studies from Tel Aviv University (2013), along with dual Bachelor of Arts (B.A.) degrees in Biochemistry and Political Science from Brandeis University (2006).
One day however a small line of blind text by the name of Lorem Ipsum decided to leave for the far World of Grammar. The Big Oxmox advised her not to do so, because
